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Abstract
Background: Evidence-based clinical research poses special barriers in the field of nutrition. The present review
summarises the main barriers to research in the field of nutrition that are not common to all randomised clinical
trials or trials on rare diseases and highlights opportunities for improvements.
Methods: Systematic academic literature searches and internal European Clinical Research Infrastructure Network
(ECRIN) communications during face-to-face meetings and telephone conferences from 2013 to 2017 within the
context of the ECRIN Integrating Activity (ECRIN-IA) project.
Results: Many nutrients occur in multiple forms that differ in biological activity, and several factors can alter their
bioavailability which raises barriers to their assessment. These include specific difficulties with blinding procedures,
with assessments of dietary intake, and with selecting appropriate outcomes as patient-centred outcomes may
occur decennia into the future. The methodologies and regulations for drug trials are, however, applicable to
nutrition trials.
Conclusions: Research on clinical nutrition should start by collecting clinical data systematically in databases and
registries. Measurable patient-centred outcomes and appropriate study designs are needed. International cooperation
and multistakeholder engagement are key for success.
Keywords: Randomised clinical trials, Evidence-based clinical practice, Evidence-based medicine, Assessment, Specific
barriers, Nutrition, ECRIN, European Clinical Infrastructure Network
Background
The European Clinical Research Infrastructure Network
Integrating Activity (ECRIN-IA) project has initiated
work to identify threats and barriers to evidence-based
clinical practice [1–3].1
We identified common barriers affecting all clinical
trials, namely inadequate knowledge and understanding
of clinical research and trial methodology; lack of fund-
ing; excessive monitoring; restrictive interpretation of
privacy law and lack of transparency; overly complex or
inadequate regulatory requirements; and inadequate
clinical research infrastructures [4]. Furthermore, we
identified barriers towards the conduct of clinical re-
search on rare diseases, including the direct conse-
quence of rarity; limited knowledge on the natural
history of rare diseases; the need for trial designs
adapted to the small population size and clinical hetero-
geneity; the need for multinational randomised clinical
trials and infrastructures to conduct such trials; the need
for more sensitive outcomes to quantify clinical benefit;
and the need for involvement of all the stakeholders in
the study design and conduct [5]. In a related paper, we
also assess the specific barriers towards clinical research
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on medical devices [6]. In the present paper, we assess
the specific barriers towards clinical research on nutri-
tion and examine how they can be broken down in order
to improve the future evidence base.
Due to the ubiquitous nature of nutrition and the mul-
tiple metabolic effects induced by each food, nutrient, or
micronutrient component, randomised clinical trials
(RCTs) in this area face practical barriers [7]. By nature,
some barriers can be difficult to resolve such as making
an appropriate placebo for blinding of the interventions.
Due to the multiple metabolic impact of nutrients,
choosing the primary outcome and the determination of
sample size may seem particularly difficult. Nutrition re-
search on products is also complex because it exploits a
multitude of bioactive compounds acting on an exten-
sive network of interacting processes. In addition to
measuring the variables of interest (assessing health), an
extensive description of the trial participants and foods
or diets consumed is essential. However, solutions exist
to respect general rules of clinical trials despite these
barriers.
The present paper gives an overview of the specific ob-
stacles in methodology within nutrition research and
provides solutions to these barriers (Table 1). The regu-
lations in this area are also discussed.
Methods
The present study is based on a combination of systematic
academic literature searches as well as internal ECRIN-IA
communications from 2013 to 2017. In May 2016, the sys-
tematic search was performed using The Cochrane Library
(Wiley) (Issue 5 of 12, 2016) (including the Cochrane Data-
base of Systematic Reviews (CDSR), CENTRAL, National
Health Service Economic Evaluation Database (NHSEED),
and Database of Abstracts of Reviews of Effects (DARE,
U.S. Library of Medicine)); MEDLINE (Ovid SP) (1946 to
May 2016); EMBASE (Ovid SP) (1974 to May 2016); and
Science Citation Index Expanded (1900 to May 2016) using
different terms covering barriers, evidence-based medicine,
and nutrition. The exact search strategy is provided in
Additional file 1. A Preferred Reporting Items for System-
atic Reviews and Meta-analyses (PRISMA) flow diagram
depicting the selection process and a PRISMA Checklist
are provided in Fig. 1 and Additional file 2, respectively.
Articles were selected if they included valid considerations
on how barriers to the conduct of randomised clinical trials




Through the electronic searches a total of 4871 references
were identified. After 589 duplicates were removed, a total
of 4282 references remained, and were further reduced to
yield 11 relevant references (Additional file 3).
Randomised clinical trials on nutrition
RCTs are costly and labourious to conduct, but they are
essential [8–11]. The RCT is the only design which is
able to demonstrate a causal relationship between a diet-
ary change and health outcomes [8–11]. However, test-
ing the effect of a diet or a specific nutrient in a trial is
not the same as testing a drug and different obstacles
are encountered (Table 1).
Testing a nutrient
If only a nutrient is tested, a placebo can be easily used,
and an RCT with blinding can be conducted. Compli-
ance can be checked by counting pills and possibly by
assaying the nutrient concentration or related functions.
However, many nutrients occur in multiple forms that
differ in biological activity, and there are several factors
that can alter the bioavailability of individual nutrients.
The nutrient status and the baseline exposure could also
cause interference. The nutrient status of an individual
or a population can affect the response to nutrient sup-
plementation, e.g., via the gastrointestinal microbiota.
For example, if one wants to examine the effect of poly-
phenol, adding polyphenol to polyphenol-depleted diets
will give a good check on polyphenol dose. However,
these special depleted diets (depleted in fruit, vegetable,
and polyphenol-containing beverages) will have con-
founding effects and there will be no real control group.
Another way will be to add polyphenol in addition to
the polyphenols of a normal diet, but then both groups
might receive sufficient polyphenol, and a possible effect
of polyphenol might be overlooked. Both types of trials
will give information, but different information. Back-
ground levels of exposures can be difficult to accurately
determine due to limitations in currently available as-
sessment methodologies of food intake, incomplete nu-
trient databases with which nutrient intake estimates are
Table 1 Barriers to the conduct of randomised clinical trials
(RCTs) on nutrition
Specific barriers to RCTs on
nutrition
Comments
Testing a nutrient Should one use the nutrient as an
add-on to usual diet, or should the
diet be depleted of the nutrient?
Testing a food intervention How to assess dietary intake
Assessing dietary intake Combination of diverse methods
including the 24-h dietary recall
method are likely to be best
Selection of outcomes Depends on the objective of
the study
Barriers as identified by the European Clinical Research Infrastructure Network
(ECRIN) panel in the context of the ECRIN-IA project. These barriers are additional
to the barriers that affect all clinical trials and trials on rare diseases [4, 5]
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calculated, and temporal changes in exposure. This must
be carefully considered in the trial design, including ran-
domisation and subgroup analysis per baseline status.
For smaller RCTs (say less than 400 to 500 participants),
adjustment according to the baseline level of consump-
tion or nutrient level in blood may be necessary [12].
Testing a food intervention
Food-based interventions are complex; an appropriate pla-
cebo for food cannot be designed so RCTs cannot easily
be blinded. However, outcome assessors, data collectors,
statisticians, and conclusion drawers should be blinded.
Furthermore, a specific design with food made with or
without the particular nutrient can be conducted.
Thus, food-based nutrition interventions, in contrast
to nutrient supplementation, present unique challenges
in accurately quantifying the absolute change in intake.
Compliance assessment in these trials is more difficult
but biomarkers of food intake may be used (alpha-lino-
lenic acid as a proxy for nut intake or some polyphenols,
such as urinary tyrosol, for virgin olive oil) [13]. Certain
periods of holidays or religious festivities (such as
Ramadan) should be avoided to reduce interference from
special nutritional patterns during such periods. The
seasonal impact on food intake also needs to be taken
into account [14]. The optimal length of intervention to
have a relevant effect can also be difficult to determine.
Here again, particular attention must be paid when test-
ing a food product, the product will not have the same
impact if it substitutes another product or if it is added
to the usual diet.
The ILSI Europe Functional Foods Task Force guide-
lines [15] are a relevant source on how to conduct nutri-
tion intervention studies and can help resolve some of
those questions.
Assessing dietary intake
Assessing dietary intake is a major challenge in nutrition
research despite the large spectrum of research method-
ologies available.
Quantification of habitual dietary exposure by measure-
ment of food intake combined with food composition is
essential for investigating the impact of food on health.
The assessment of dietary intake at the population level
Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2009 flow diagram. PRISMA flow diagram depicting the
selection process of relevant academic literature
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provides important information on the frequency and
distribution of inadequate diets and nutritional status and
guides the design of population-based interventions tar-
geting the improvement of dietary habits at the commu-
nity level. Obtaining reliable data on food consumption
(identifying the intake of energy and nutrients) is a key
factor and a necessary tool in health promotion and pre-
diction of disease risk [16].
Difficulties are encountered in the assessment of dietary
intake. Valid methods are required to assess the effects of
a huge range of diverse foods and compounds (macro-
and micronutrients, and non-nutritional bioactive com-
pounds) on individual health. A wide variety of dietary
survey methods exists, with each one presenting a series
of advantages and disadvantages that must be taken into
consideration based on the study aims, the degree of pre-
cision needed and the available resources. Common
methods involving dietary questionnaires are:
 Food frequency
 24-h recall
 Dietary history over a specific period
 Food diary associated with photographic food record
 Weighed food record
 Specific dietary items or patterns
The validity of these approaches has been questioned
many times [17]. A volunteer assessing their dietary in-
take may modify their eating behaviour, thus introducing
an another issue in dietary assessment. Dietary intake is
difficult to measure and a single instrument that is opti-
mal for all settings does not exist, as each method has
its pros and cons or practical difficulties that should be
taken into account when selecting the instrument to be
administered. For example, a weighed-food record is
precise but rather cumbersome for the volunteers and
can lead to underreporting. The method used could be
improved by using more frequent dietary recall.
Expectations for better assessment of dietary intake are
put on new methods, such as research in metabolomics,
metagenomics, and natural enrichment of stable isotopes,
which could be helpful in terms of the validation of
methods and useful in addition to standard methods.
Technological devices, such as cellular phones, may also
improve the quality of data collected. The majority of
the latest-generation technologies offer interesting tools
for the process of evaluating dietary intake in epidemio-
logical studies [18–21]. The advantages of digital in-
struments include: (1) reduction in interviewer bias; (2)
reduction in the time and cost of field work; (3) data
collection and codification in real time; (4) automatic
calculation of daily intake; and (5) highly economic op-
tions of capturing food intake online (computer, tablet,
and smartphone).
New technologies provide many possibilities for asses-
sing dietary intake in individuals and groups, but are not
free of certain limitations: high cost of programme de-
sign and acquisition of devices; difficulty of application
to certain populations that are not familiar with new
technologies; and dependence on access to Internet and
on the trial participant’s recall capacity.
Despite the interesting progress and the incorporation
of innovative technology into dietary assessment methods,
the same flaws remain. As such, the combination of di-
verse methods could be the best approach, with the 24-h
dietary recall being a rather reliable comprehensive and
easy-to-use instrument [22–24].
Research over recent years in this field has focussed
on estimating the adherence to a determined dietary pat-
tern rather than analysing the individual components of
the diet in relation to the health of the population. Many
indirect indices have been proposed. These indices sum-
marise the diet by means of a single score that results
from a function of numerous components (previously
selected on the basis of prior knowledge or scientific evi-
dence) such as food, food groups, or a combination of
foods and nutrients [25]. The validity of these indices
has been evaluated by examining their relationship with
nutrient adequacy and several health outcomes (i.e.,
nutrient-related diseases). For instance, indices eva-
luating adherence to the Mediterranean diet, like the
Mediterranean food pattern PREDIMED study (MeDiet-
PREDIMED) [26], the Mediterranean Adequacy Index
(MAI) [27], the Mediterranean Diet Score (MDS) [28],
or the Mediterranean Diet Quality Index (KIDMED) for
evaluating the quality of the Mediterranean diet in children
and adolescents [29], have been successfully applied to
studies on life expectancy [30], cardiovascular risk [31–33],
cancer [34, 35], hypertension [36], obesity [37, 38], and
diabetes [39]. The study of dietary patterns using dietary
quality indices to examine interactions between dietary
components and their effect on several health variables can
be complementary to the analysis of single dietary compo-
nents [40, 41]. Moreover, these indices are also useful tools
to measure food consumption trends and to identify the
involved factors, as well as to develop comprehensive pub-
lic health nutrition recommendations.
Approaches to evidence-based medicine, with its re-
liance on RCTs and systematic reviews of RCTs [1] have
been adapted to nutrition systematic reviews and policy
[42–45]. However, there are distinct differences between
the evidence that can be obtained for the testing of
drugs using RCTs and those needed for the development
of nutrient requirements or dietary guidelines [46]. Nu-
trients tend to work in systems in concert with other
nutrients and affect multiple cells and organs; nutrients
are homeostatically controlled and thus the body’s base-
line nutrient ‘status’ affects the response to a nutrient
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intervention; a nutrient intervention group cannot be
contrasted with a true placebo group (i.e., a ‘zero-expo-
sure’ group). The subtle effect of nutrients and small
effect sizes means that far more participants are needed
to demonstrate statistical significance depending on the
research question and the target population.
Chronic diseases can take decades to develop, so dem-
onstrating a statistically significant and clinically relevant
reduction in risk with any intervention requires very
long-term trials. Moreover, maintaining adherence to a
dietary change all through a trial period is difficult. RCTs
present one approach toward understanding the efficacy
of nutrient interventions, but the innate complexities of
nutrient actions and interactions cannot always be ad-
equately addressed through a single research design.
Outcomes
Outcomes could vary according to the objectives of a
study. In mechanistic proof-of-concept studies, they
could be very specific and explanatory [47]. The sample
size should be calculated according to the variability of
the measured primary outcome which could be either a
single outcome or a composite outcome.
Secondary outcomes should have enough power (at
least 80%) to determine a conclusion; if not, they should
only be used as exploratory outcomes [1]. Outcomes
should concern nutritional status, relevant markers of
functional status, quality of life, morbidity, and mortality.
Hard outcomes should always be preferred when asses-
sing the effects of clinical nutrition interventions,
whereas intermediate markers might be used in addition
to hard outcomes in preventive nutrition.
Numerous experimental nutrition studies have used
putative surrogate outcomes and markers of disease risk,
but only a few such markers have been validated using
hard outcomes [1]. Nutrition research needs better bio-
markers of both exposures and outcome. Defining ap-
proved panels of outcomes for particular health
outcomes would allow easier conduct of systematic re-
views and meta-analyses. It is mandatory to have precise
outcomes to predefine the moment of their measure-
ment, as is the case for all types of research, and to de-
cide them before commencing RCTs [1].
For dietary supplements and functional food, studies
could also target non-diseased populations. Statistically,
however, there are challenges in performing studies in a
non-diseased, healthy population. In healthy volunteers,
the magnitude of functional changes and their clinical
relevance are likely to be more difficult to highlight than
it would be in diseased participants and the likelihood of
demonstrating a statistically significant difference is
diminished. Experimental designs including metabolic
challenges (such as short-term overfeeding or a fat or
fructose load) could be useful to screen for the
protective effect of some nutrients. Studies in high-risk
populations are encouraged.
The need to accurately capture subtle changes in a
multitude of variables creates several challenges. Standar-
dised technology, methodology, and data formats are re-
quired for meeting these challenges. Elements of these
issues are common to all biological sciences and efforts to
produce solutions and best practices for technologies and
data handling in these areas are under investigation [48].
Single-centre trials are easier to conduct than multi-
centre trials and may be done more efficiently with a
homogenous population. However, they have less exter-
nal validity and often do not reach a required sample
size. Accordingly, it is often necessary to organise multi-
centre trials in order to achieve an adequate sample size.
In general, results from a multicentre trial will be more
convincing than those coming from a single centre.
Solutions to the specific problems of nutrition research
could be solved by the extension of good clinical re-
search practice and harmonising procedures.
System studies and observational studies
Observational studies derived from large epidemiological
surveys are able to raise hypotheses in terms of the associ-
ation between dietary patterns and health outcomes [49].
These hypotheses, as well as other hypothesis derived
from experimental research, should be the basis for RCTs.
More and more observational and epidemiological
studies, which are carried out on a dietary basis, have
attempted to associate the intake of particular food
group with disease prevalence. The results are rarely
unidirectional, and it still remains unclear whether cer-
tain food groups may be considered as definitively pro-
tective or deleterious. Therefore, a more holistic
approach based on cumulative scientific evidence, i.e.,
data mining, may be needed [50]. This global approach
draws updated pictures on the research led on such asso-
ciations and helps to unravel research needs. For instance,
based on meta-analyses and systematic reviews of articles
from 1950 to 2013 referring to observational and inter-
vention studies, we were able to identify tendencies related
to the health-protectiveness of 17 food groups and bever-
ages towards 10 disease risks [51]. Among these tenden-
cies, some can be considered as strong and may
potentially be converted into clear and durable recom-
mendations for public policies related to preventive nutri-
tion and health, while others remain ambiguous.
Another important aspect of nutrition research is that
exposure to specific food groups or nutrients may induce
metabolic disorders long before any non-communicable
chronic disease may be detected in relation to the diet.
The origins of these diseases are multifactorial and may
result from at least 10 different deregulated metabolic var-
iables, including antioxidant status, acid-base imbalance,
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increased inflammatory status, impaired carbohydrate/
lipid/one-carbon metabolism, impaired functioning of
neurons and deoxyribonucleic acid (DNA) transcription,
hypertension and/or modified digestive microbiota [52].
Such a systems approach represents an important oppor-
tunity to identify early biomarkers of future chronic dis-
eases in association with dietary nutrients. So,
technological development allowing rapid and large
screening of metabolites, i.e., metabolomics, in plasma or
urine samples, will likely be of high value for detecting
dietary risk factors in individuals [53].
Regulations
The level of the quality of nutrition research is also
dependent on regulations and practices that have been
approved by EFSA (The European Food Safety Author-
ity). The authority has indicated a preference for clinical
studies to back health claims [13]. Placebo-controlled
trials are the ‘gold standard’ with either a parallel or
crossover design. RCTs involving whole foods or diets
are difficult to conduct, perhaps even more so than
nutrient-based trials, but for the same reasons: lack of
compliance, no true placebo group, and the impossibility
of having a control group. Furthermore, the innate com-
plexities of nutrient actions and interactions cannot al-
ways be adequately addressed through any single
research design.
Good clinical practice is applicable to interventional
research beyond health products, particularly in nutri-
tion, to ensure the reliability and reproducibility of the
data and to safeguard the rights and safety of research
participants and the confidentiality of information that
concern them [54, 55].
The great heterogeneity of national regulations regard-
ing non-drug research mainly depends on the consider-
ation of a dietary supplement as a drug or not and the
level of intervention imposed on the patient. There is a
need to harmonise the procedures for evaluating nutri-
tion clinical trials in Europe. One of the deliverables of
WP6 within ECRIN-IA has been to collect the different
national regulation requirements and develop a pan-
European human nutrition regulatory and ethics data-
base [56].
For the US Food and Drug Administration (FDA), if
an Investigational New Drug (IND) is needed for a clin-
ical investigation, evaluating a dietary supplement is de-
termined by the intent of the clinical investigation. If the
clinical investigation is intended only to evaluate the
dietary supplement’s effect on the structure or function
of the body, an IND is not required. However, if the clin-
ical investigation is intended to evaluate the dietary sup-
plement’s ability to diagnose, cure, mitigate, treat, or
prevent a disease, an IND is required under part 312
[54]. The European Commission has now adopted a
revision of the Directive on Clinical Trials (2001-20-EC)
17 July 2012 [57], Regulation EU No. 536/2014 which
will come into force in 2019 at the earliest [58]. This
should facilitate the conduct of multinational clinical tri-
als with particular attention to the acceleration and sim-
plification of licensing and reporting clinical trials
procedures. Through this proposed regulation, it will be
possible to ensure, in all member states, identical rules
for the authorisation, execution, and monitoring of clin-
ical trials.
Conclusions
Nutrition research must apply reproducible and valid
methodologies [8, 15]. The methodologies and regulations
for drug trials are applicable to trials in the field of nutri-
tion. A consensual approach involving institutional and in-
dustrial partners of the clinical nutrition research would
be useful for standardisation of these practices on specific
aspects such as the choice of a placebo, the design of the
test products, the selection of control participants, the
choice of outcomes, and sample size estimation. In collab-
oration with ECRIN, it will be necessary to standardise
nutritional and outcome assessment, standardise operat-
ing procedures for existing and new methodologies, and
standardise data collection, data management and data
sharing, which will make studies comparable and inter-
operable for systematic reviews meta-analyses.
Taking into account the specificities of nutrition stud-
ies and developing international collaboration will en-
hance the quality of nutrition research [1].
Endnotes
1Funded by the European Union Framework
Programme 7 (EU FP7; grant agreement no. 284395),
ECRIN-IA involved 23 countries and brought together
diverse stakeholders to overcome barriers to clinical re-
search in three particularly difficult areas (rare diseases,
medical devices, and nutrition). Specifically, the project
aimed to develop tools, services, and infrastructure to fa-
cilitate multinational clinical research in Europe, and to
support the development of pan-European disease net-
works to drive clinical projects. This in turn was
intended to improve Europe’s attractiveness to industry,
boost its scientific competitiveness, and result in better
health care for European citizens. Originally planned for
4 years (2012 to 2015), the clinical trials work package
was extended until 2017.
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